<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02452099</url>
  </required_header>
  <id_info>
    <org_study_id>COI-DMSO-01</org_study_id>
    <nct_id>NCT02452099</nct_id>
  </id_info>
  <brief_title>Impact of DMSO Concentrations on Hematopoietic Recovery After Autologous HSC Transplantation.</brief_title>
  <acronym>DMSOconc3</acronym>
  <official_title>Impact of Different DMSO Concentrations in Cryopreservation Mixture on Hematopoietic Recovery After Autologous Transplantation of Hematopoietic Stem Cells.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maria Sklodowska-Curie Institute - Oncology Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maria Sklodowska-Curie Institute - Oncology Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of the study was to evaluate the clinical impact of different DMSO
      concentrations in cryopreservation mixture (5%, 7.5%, 10%) on reconstitution of hematopoiesis
      after autologous hematopoietic stem cell transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The procedure of autologous hematopoietic stem cell (HSC) transplantation requires
      cryopreservation of HSCs. Addition of DMSO (dimethyl sulfoxide) is necessary to secure the
      viability of such cells, but this cryoprotectant is potentially toxic to stem cell recipient.
      The concentrations of DMSO in cryopreservation mixture vary strongly between protocols in
      different transplant centers. Usually, the HSCs are stored in mixtures containing 10% DMSO,
      but there is no sufficient evidence that this concentration of DMSO is indeed optimal.

      The main aim of the study is to evaluate the clinical impact of reduction of DMSO
      concentration in cryopreservation mixture on engraftment after autologous hematopoietic stem
      cell transplantation. 150 consecutive patients will be randomly assigned to one of three
      study arms (50 patients each). HSCs obtained by leukapheresis will be cryopreserved in three
      concentrations of DMSO: 5%, 7.5%, 10%, respectively. Evaluation of the mixtures will be
      carried out by monitoring reconstitution of hematopoiesis and the frequency the side effects
      in patients. The most important aspect of our evaluation will be the speed of neutrophil
      recovery after transplantation (defined by the first day, when absolute neutrophil count in
      peripheral blood will be higher than 0.5 G/L). The investigators will also evaluate the
      toxicity of cell suspension by monitoring the frequency of infusion-related adverse events
      (like nausea or vomiting) during infusion and 24 hours after transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The median time to neutrophils recovery after autoHSC transplantation.</measure>
    <time_frame>The first from 3 consecutive days, on which absolute neutrophil count in peripheral blood will be higher than 0.5 G/L</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The median time to platelets recovery after autoHSC transplantation.</measure>
    <time_frame>The first from 3 consecutive days, on which platelet count in peripheral blood will be higher than 20 G/L, without platelet transfusion 7 days prior.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions related with transplantation procedure</measure>
    <time_frame>24 hours after transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Lymphomas</condition>
  <condition>Leukemias</condition>
  <arm_group>
    <arm_group_label>5% DMSO</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>7.5% DMSO</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10% DMSO</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryopreservation of HSCs using 5% DMSO concentration</intervention_name>
    <description>Cryopreservation of HSCs obtained by leukapheresis will be performed using 5% DMSO concentration.</description>
    <arm_group_label>5% DMSO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryopreservation of HSCs using 7,5% DMSO concentration</intervention_name>
    <description>Cryopreservation of HSCs obtained by leukapheresis will be performed using 7,5% DMSO concentration.</description>
    <arm_group_label>7.5% DMSO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryopreservation of HSCs using 10% DMSO concentration</intervention_name>
    <description>Cryopreservation of HSCs obtained by leukapheresis will be performed using 10% DMSO concentration.</description>
    <arm_group_label>10% DMSO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with hematological malignancies or solid tumors, refered for autologous HSC
             transplantation

          -  Written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MSC Memorial CAncer Center and Institute of Oncology</name>
      <address>
        <city>Gliwice</city>
        <zip>44-101</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <results_reference>
    <citation>Smagur A, Mitrus I, Ciomber A, Panczyniak K, Fidyk W, Sadus-Wojciechowska M, Holowiecki J, Giebel S. Comparison of the cryoprotective solutions based on human albumin vs. autologous plasma: its effect on cell recovery, clonogenic potential of peripheral blood hematopoietic progenitor cells and engraftment after autologous transplantation. Vox Sang. 2015 May;108(4):417-24. doi: 10.1111/vox.12238. Epub 2015 Mar 6.</citation>
    <PMID>25753814</PMID>
  </results_reference>
  <results_reference>
    <citation>Mitrus I, Smagur A, Giebel S, Gliwinska J, Prokop M, Glowala-Kosinska M, Chwieduk A, Sadus-Wojciechowska M, Tukiendorf A, Holowiecki J. A faster reconstitution of hematopoiesis after autologous transplantation of hematopoietic cells cryopreserved in 7.5% dimethyl sulfoxide if compared to 10% dimethyl sulfoxide containing medium. Cryobiology. 2013 Dec;67(3):327-31. doi: 10.1016/j.cryobiol.2013.09.167. Epub 2013 Oct 11.</citation>
    <PMID>24125911</PMID>
  </results_reference>
  <results_reference>
    <citation>Smagur A, Mitrus I, Giebel S, Sadus-Wojciechowska M, Najda J, Kruzel T, Czerw T, Gliwinska J, Prokop M, Glowala-Kosinska M, Chwieduk A, Holowiecki J. Impact of different dimethyl sulphoxide concentrations on cell recovery, viability and clonogenic potential of cryopreserved peripheral blood hematopoietic stem and progenitor cells. Vox Sang. 2013 Apr;104(3):240-7. doi: 10.1111/j.1423-0410.2012.01657.x. Epub 2012 Oct 9.</citation>
    <PMID>23046417</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2015</study_first_submitted>
  <study_first_submitted_qc>May 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2015</study_first_posted>
  <last_update_submitted>January 17, 2017</last_update_submitted>
  <last_update_submitted_qc>January 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maria Sklodowska-Curie Institute - Oncology Center</investigator_affiliation>
    <investigator_full_name>Sebastian Giebel</investigator_full_name>
    <investigator_title>Prof., MD</investigator_title>
  </responsible_party>
  <keyword>DMSO</keyword>
  <keyword>cryopreservation</keyword>
  <keyword>autologous transplantation</keyword>
  <keyword>hematopoietic stem cells</keyword>
  <keyword>hematological malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dimethyl Sulfoxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

